A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer.
Fury
Matthew G
MG
Head and Neck Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. furym@mskcc.org
Haque
Sofia
S
Stambuk
Hilda
H
Shen
Ronglai
R
Carlson
Diane
D
Pfister
David
D